You are viewing the site in preview mode

Skip to main content

Table 2 Trough concentrations of vancomycin and CDP-1 in serum

From: Factors associated with serum concentrations of vancomycin crystalline degradation product (CDP-1) among patients with chronic kidney disease

Variables

Total (n = 167)

G1 (n = 49)

G2 (n = 69)

G3 (n = 49)

P

CDP-1, μg/mL

1.56 ± 1.80

0.83 ± 0.78

1.29 ± 0.92

2.67 ± 2.73

<0.001

  CDP-1-m, μg/mL

0.64 ± 0.64

0.38 ± 0.08

0.54 ± 0.07

1.01 ± 0.08

<0.001

  CDP-1-M, μg/mL

0.93 ± 1.18

0.45 ± 0.15

0.74 ± 0.13

1.66 ± 1.36

<0.001

Vancomycin (UPLC-MS/MS), μg/mL

24.87 ± 16.06

18.48 ± 10.94

23.66 ± 11.95

32.63 ± 21.69

<0.001

Vancomycin (CMIA), μg/mL

27.80 ± 20.48

20.24 ± 12.97

25.63 ± 13.98

38.08 ± 28.63

<0.001

VCMIA/VUPLC-MS/MS ratio

1.09 ± 0.10

1.06 ± 0.08

1.08 ± 0.09

1.12 ± 0.12

0.008

C/VUPLC-MS/MS ratio, %

5.65 ± 2.50

4.18 ± 1.40

5.12 ± 1.46

7.88 ± 3.10

<0.001

  1. CDP-1: Crystalline degradation product, CDP-1-m: Crystalline degradation product the minor isomer. CDP-1-M: Crystalline degradation product the major isomer, UPLC‒MS/MS: Ultra-high performance liquid chromatography tandem mass, VCMIA/VUPLC-MS/MS: The ratio of vancomycin concentration by chemiluminescence microparticle immunoassay to vancomycin concentration by ultra high liquid chromatography‒tandem mass spectrometry, C/VUPLC-MS/MS: The ratio of crystalline degradation products trough concentration to vancomycin trough concentration by ultra-high performance liquid chromatography‒tandem mass spectrometry